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Abstract
Pancreatic ductal carcinoma is one of the most lethal malignancies, but in recent years a number of positive 
developments have occurred in the management of pancreatic carcinoma. This article aims to give an overview of the 
current knowledge regarding the role of radiotherapy in the treatment of pancreatic ductal adenocarcinoma (PDAC). 
The results of meta-analyses, phase III-studies, and phase II-studies using chemoradiotherapy and chemotherapy for 
resectable and non-resectable PDAC were reviewed. The use of radiotherapy is discussed in the neoadjuvant and 
adjuvant settings as well as in the locally advanced situation. Whenever possible, radiotherapy should be performed as 
simultaneous chemoradiotherapy. Patients with PDAC should be offered entry into clinical trials to identify optimal 
treatment results.
Introduction
Despite considerable progress in oncology, the poor
prognosis of patients with pancreatic ductal adenocarci-
noma (PDAC) has not significantly improved. In Europe
and the USA, PDAC is still ranked fourth and in the UK
sixth for cancer associated mortality[1,2]. More than 80%
of patients with PDAC present with irresectable disease.
One third of these patients have locally advanced pancre-
atic carcinoma (LAPC), the rest have distant metastases.
In this article we review the role of radiotherapy (R T),
currently used as chemoradiotherapy (CRT) in the man-
agement of pancreatic cancer.
We discuss its neoadjuvant use in improving resectabil-
ity rates, its adjuvant use in maintaining local control and
its role as primary treatment of LAPC. To identify eligible
studies we undertook a Medline database search from
1980 to 2008 and also included unpublished meeting
reports of phase III trials. Wherever possible we focused
on the data available from prospectively randomised
phase III trials. However for some aspects of treatment,
data was not available from prospectively randomised
phase III trials and therefore some studies with a lower
degree of evidence needed to be included. Before
addressing the respective treatment situations (adjuvant,
neoadjuvant or definitive) general matters concerning all
stages of disease are highlighted in the introduction.
Diagnostic imaging and disease staging
A number of imaging modalities may be useful in arriving
at a diagnosis in patients presenting with symptoms or
signs suggestive of pancreatic carcinoma[3]: Ultrasound,
Endoscopic UltraSound (EUS), Endoscopic Retrograde
CholangioPancreatography (ERCP), multidetector com-
puted tomography (CT) and Magnetic Resonance Imag-
ing (MRI) including Magnetic Resonance
CholangioPancreatography (MRCP). The two most sensi-
tive techniques to detect pancreatic carcinoma are multi-
detector CT and MRI in combination with MRCP. If
performed by experienced investigators EUS can reach
even higher sensitivity. It is recommended that centres
use the imaging modality with which they have most
experience. Biopsy proof of a pancreatic mass is not
required if the mass is resectable except within neoadju-
vant treatment protocols. However, histological proof is
mandatory prior to the initiation of any palliative treat-
ment. Tissue can be obtained either via EUS or CT-
guided biopsy or percutaneously[4]. For preoperative
assessment of local tumour spread and resectability,
multi-detector CT and EUS represent the best staging
tools[5]. Additionally, a chest x-ray is required if the tho-
rax is not included in the CT scan of the abdomen. * Correspondence: thomas.brunner@rob.ox.ac.uk
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Surgical technique and histopathological analysis
Resectability is the most important initial therapeutic
decision. The infiltration of adjacent organs, e.g. duode-
num or stomach, in itself does not exclude resection. Very
often resectability depends on vascular involvement [6].
Tumours infiltrating the coeliac trunk or the superior
mesenteric artery are very rarely resectable whereas infil-
tration of the portal vein often does not exclude resec-
tion. However a systematic review has shown that even if
the tumour is technically resectable the 5 year survival
rate of patients undergoing resection with involvement of
the portal and superior mesenteric veins is very low[7].
Infiltration of the superior mesenteric vein often prevents
a margin negative (R0) resection. Preoperative biliary
drainage with a stent is only necessary when the patient
suffers from cholangitis or if the operation cannot be per-
formed immediately. The recommendations to surgeons
so as to achieve an R0 resection is to allow an excision
margin of 10 mm for pancreatic tissue, bile ducts, and
stomach [8], however for anatomic reasons there are no
definite recommendations for the retroperitoneal margin.
For pancreatic head tumours the resection consists of a
duodenopancreatectomy with or without preservation of
the pylorus. In rare cases when the carcinoma extends to
the body of the pancreas a total pancreatectomy may be
necessary. Classic Whipple's procedure and pylorus pre-
serving techniques are equivalent with respect to post-
operative complications and lethality as well as long-term
survival [9]. Distal pancreatectomy is performed for
tumours of the pancreatic tail, whilst tumours of the pan-
creatic body require a subtotal distal pancreatic resection
or a total duodenopancreatectomy. Radical extended
lymphadenectomy has not been proven to result in pro-
longed survival [10]. Standard lymphadenectomy for a
Whipple's procedure for a tumour of the pancreatic head
comprises the following compartments: Complete and
circular resection of the nodes of the hepatoduodenal lig-
ament, around the common hepatic artery, around the
portal vein and the cranial aspect of the superior mesen-
teric vein. Furthermore, the right coeliac trunk lymph
nodes and the right hemi-circumference of the trunk of
the superior mesenteric artery are dissected. Resection
should be abandoned if distant metastases are encoun-
tered intraoperatively.
The pancreatic margin and the margin of the biliary
duct should always be histologically evaluated intraoper-
atively (e.g. by frozen section). Putative liver metastases
or peritoneal carcinomatosis should also be evaluated
intraoperatively with frozen section. The full histological
report should include: pT, pN, number of analysed lymph
nodes, nodal micrometastases, R-classification (tumour
status at the resection surface to the remaining pancreas,
retroperitoneal tumour status) and lymphovascular inva-
sion, vascular invasion and perineural invasion [8].
Histological assessment to diagnose a clear resection
margin (R0) should include the hepatic duct and the pan-
creatic resection surface (including the retroperitoneal
margin). To facilitate orientation the retroperitoneal mar-
gin should be ink-marked at the time of resection.
Radiotherapy technique, quality assurance, target volume 
selection, dose fractionation and normal tissue toxicity
Radiotherapy for pancreatic carcinoma should always be
performed as chemoradiotherapy, except for the rare
cases of palliative treatment of bone metastasis. Palliative
analgesic treatment of the pancreas with hypofraction-
ated radiotherapy only (20 Gy in 5 fractions) is used in the
UK however there is no evidence from the literature sup-
porting this practice. Patients who are not treated within
clinical trials should have infusional 5-fluorouracil (5-FU)
or capecitabine for chemoradiotherapy [8]. In order to
avoid toxicity, radiotherapy should be conventionally
fractionated (1.8 - 2 Gy/fraction, total dose 50 to 55 Gy).
However a hypofractioned regimen (30 Gy in 10 frac-
tions) was reported to be safe by the MD Anderson Can-
cer Center group[11]. Treatment planning should be 3D-
conformal and IMRT is recommended. Total dose was
increased up to >60 Gy using multiple field techniques or
IMRT together with restrictive target volume defini-
tions[12] however we recommend to keep total doses to
the primary tumour to 50 - 55 Gy in conventional frac-
tionation outside of clinical studies. The most important
normal tissue toxicities encountered or to be avoided are
haematotoxicity, duodenal and gastric ulceration/bleed-
ing, diarrhoea, renal and hepatic toxicity. Recommended
dose limits for critical organs are:
• Liver: 50% of the volume ≤30 Gy
• Kidneys: One kidney no more than maximally 50% 
of the volume should receive >20 Gy Other kidney no 
more than maximally 30% of the volume should 
receive >20 Gy
• Spinal cord: ≤45 Gy.
To date there is no consensus as to whether regional
lymphatics need to be emcompassed in the irradiation
target volume and if so which areas need to be covered.
Up to 80% of all resectable pancreatic head tumours have
regional lymphatic metastasis, which suggests that inclu-
sion of lymphatics may enhance locoregional control. The
distribution of the frequency of metastases in 175 resect-
able tumours was posterior pancreaticoduodenal area
(37%), superior (25%) and inferior margin of the pancre-
atic head (24%), anterior pancreaticoduodenal area (23%),
upper para-aortic (22%), hepatoduodenal ligament (18%),
superior margin of the pancreatic body (11%), and supe-
rior mesenteric artery(10%)[13]. Most of these regions,
with the exception of the hepatoduodenal ligament and
the upper paraaortic nodes, are probably within the 80%
isodose volume even when elective nodal irradiation isBrunner and Scott-Brown Radiation Oncology 2010, 5:64
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al[14]. The field design in pancreatic carcinoma requires
diligence and the total volume needs to be carefully
restricted to avoid unnecessary toxicities. With a careful
field design the primary tumour and the elective lym-
phatics can be encompassed in a treatment volume below
600 mL in most patients [13], e.g. in our institution the
maximum planning target volume (PTV) that we allow is
800 mL but most patients will have a smaller volume. The
tolerance of gemcitabine based concurrent CRT is highly
dependent upon the total treatment volume in pancreatic
carcinoma [15]. Excess toxicities have been reported if
the radiotherapy techniques have not paid sufficient
attention to these rules. Careful, active supportive ther-
apy is essential in ensuring the tolerability and effective-
ness of concurrent CRT. This comprises stenting of the
common bile duct, anti-emetic treatment, proton-pump
inhibitor therapy, analgesia and parenteral feeding if nec-
essary. When radiotherapy techniques are unfamiliar or
complex, as in pancreatic carcinoma, problems with the
quality of the delivered radiotherapy are more likely.
Quality assurance in radiotherapy for pancreatic cancer
should comprise standard dosimetry assessments, ade-
quate PTV coverage and adequate protection of normal
tissue structures [16]. An example to highlight the signifi-
cance of radiotherapy quality assessment is the lack of a
description in the protocol for radiotherapy technique,
normal tissue constraints and quality assessment within
the adjuvant ESPAC-1 trial where chemoradiotherapy
appeared to be detrimental to the patient[17]. This detri-
mental effect could be due to both geographical miss and
increased radiotherapy toxicity.
Adjuvant Chemoradiotherapy
Adjuvant (after R0-resection) or additive chemoradio-
therapy (after R1- or doubtful complete resection) aims
to prolong survival by improved local tumour control. A
total of seven randomised controlled trials have been
published to date. The most important of these are the
Gastrointestinal Tumour Study Group (GITSG) trial[18],
the European Study Group for Pancreatic Cancer
(ESPAC-1) trial[17], the Charité Onkologie (CONKO-
001) trial[19] and recently the Radiation Therapy Oncol-
ogy Group (RTOG 97-04) trial[20]. We have not included
the small Norwegian Pancreatic Cancer Trial Group
study [21] and the EORTC trial where about half of the
patients had periampullary and not pancreatic carcinoma
[22]. The trial that is likely to have had the largest impact
on adjuvant chemoradiotherapy in UK practice is the
ESPAC-1 trial of adjuvant treatment for pancreatic can-
cer[17,23]. This trial recruited patients from 53 hospitals
in a 2 × 2 factorial design. There were four study groups
which included (1) surgery only (n = 69), (2) chemother-
apy with 5-FU (5-FU bolus and leucovorin d1-5q29 for
six cycles) (n = 73), (3) 5-FU based chemoradiotherapy
according to the GITSG [18] method (n = 73), and (4)
both treatments (chemoradiotherapy followed by chemo-
therapy) (n = 73). The randomisation process of ESPAC-1
was rather complicated. In the first report of this trial[23]
non-randomised patients were included, who had been
allowed to choose their treatment option, and we will
therefore not discuss the results further. However in the
second report only correctly randomised patients were
included into the analysis[17]. The survival results were
given as five-year survival rates which were 8% for
patients not receiving chemotherapy, 21% for those
receiving chemotherapy, and 10% among patients who
received chemoradiotherapy. However the interpretation
of the data is very difficult because the control groups
contain a mix of subpopulations, e.g. chemotherapy is
compared to patients having had surgery only or having
had chemoradiotherapy. The authors concluded that
adjuvant chemotherapy prolonged survival whereas
chemoradiotherapy had a negative effect on survival.
Patients with adjuvant chemoradiotherapy alone
achieved a median OS of 13.9 months, lower than the
reported 16.9 months after surgery alone. In ESPAC-1,
survival after adjuvant chemoradiotherapy was shorter
than the median OS (15 months) of patients with LAPC
who were treated with combined chemotherapy and
chemoradiotherapy without resection [24]. The report
says that chemoradiotherapy was performed according to
'local quality-assurance procedures in place', and this
might explain the detrimental effect of chemoradiother-
apy. The radiotherapy delivered in this trial was subopti-
mal using a technique which was conceived in the early
1970s: the split-course technique, prolonging treatment
time, is known to reduce the rate of local control. The
total dose employed was only 40 Gy, and 5-FU was given
as a bolus injection schedule which is known to be infe-
rior to prolonged intravenous infusional schedules. 3-D
conformal treatment planning techniques were available
at the time when the study was conducted but were not
used, and even simple parallel opposed Ant.-Post. tech-
niques were allowed within this trial. A good example of
how improvements in quality assurance and technique
can affect chemoradiotherapy in upper gastrointestinal
tumours is the successful introduction of such techniques
into the adjuvant treatment for stomach cancer [25].
Therefore we believe that the ESPAC-1 trial cannot
answer the question as to the role adjuvant chemoradio-
therapy plays in the treatment of resected pancreatic car-
cinoma.
The results of the RTOG 97-04 study were published in
2008 [20]. This study tested whether the effect of adju-
vant 5-FU based chemoradiotherapy (50.4 Gy; 250 mg 5-
FU/m²/day continuous infusion) could be enhanced by
adding gemcitabine for three weeks pre-CRT and for 12Brunner and Scott-Brown Radiation Oncology 2010, 5:64
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weeks post-CRT (G-arm) whereas the control arm con-
tained pre-CRT and post-CRT 5-FU chemotherapy. The
principal question was therefore chemotherapeutic and
randomisation included stratification according to
tumour diameter (<3 cm vs ≥3 cm), nodal status, and sur-
gical margins.. In contrast to the ESPAC-1 study, pro-
spective quality assurance of radiotherapy was required
for all patients and current radiotherapy techniques were
used. The analysis comprised 442 patients. The median
overall survival (OS) of patients with tumours of the pan-
creatic head was significantly longer in the G-arm com-
pared to the control arm with 5-FU chemotherapy (20.6
vs. 16.9 months, 32% vs. 21% after 3 years; p = 0.033)
however not if tumours of the pancreatic body or tail
were included. On multivariate analysis three parameters
reached statistical significance: the treatment arm (p =
0.025), the nodal status (p = 0.003) and the maximal
tumour diameter (p = 0.03). The non-haematological tox-
icity (>Grade 3) did not differ between the two arms.
Grade 4 haematotoxicity was 14% in the gemcitabine arm
and 2% in the 5-FU arm, without any difference in the
rate of febrile neutropenia. This trial, has changed stan-
dard adjuvant therapy in the US for tumours of the pan-
creatic head: Currently, for the National Cancer Institute,
standard treatment is radical pancreatic resection with or
without post-operative 5-fluorouracil chemotherapy and
radiation therapy[26]. For the National Comprehensive
Cancer Centers Network (NCCN), standard adjuvant
treatment options are systemic gemcitabine followed by
chemoradiation (5-FU-based) or  chemotherapy alone
(gemcitabine preferred or 5-FU/leucovorin or capecit-
abine)[27].
Compared to ESPAC-1, RTOG 97-04 included patients
with a more unfavourable distribution of risk factors
(resection status, pN-category and largest tumour diame-
ter) but nevertheless resulted in longer survival. Superior
quality and technique of chemoradiotherapy may explain
this difference. The improved radiotherapy technique
employed in the RTOG trial is reflected in the reduction
of local recurrence rates being 25% in the RTOG trial
compared to 47% in the GITSG trial and 62% overall in
the ESPAC-1 trial. Remarkably, the rate of positive mar-
gins after resection was almost twice as high in the
RTOG-trial (35%) compared to the CONKO-001 trial
(19%) in the respective experimental arms but this was
without a reduction of survival in this comparison, prob-
ably due to the radiotherapy element. The CONKO-001
trial comparing chemotherapy only with observation
reported a local recurrence rate of approximately 38% in
both arms (34% with adjuvant treatment and 41% with-
out) which is considerably higher compared to the RTOG
trial. Of course, many of these local recurrences are not
isolated. Therefore it can be hypothesised that more
effective systemic treatment controlling systemic disease
could benefit considerably from combination with effec-
tive radiotherapy. Despite a median disease-free survival
time of 13 months with adjuvant gemcitabine vs 7
months without (p < 0.001), there was not a statistically
significant difference in overall survival in the CONKO-
001 trial. The disease-free survival effect was observed in
both the R0 and the R1 resection subgroups.
To date, there are two meta-analyses addressing adju-
vant chemoradiotherapy in pancreatic carcinoma which
result in discrepant conclusions. The discrepancies could
be explained by the predominance of the randomised and
non-randomised ESPAC-1 patients in the meta-analysis
from Stocken et al [28] on the one hand and by the inclu-
sion of the non-randomised Yeo et al data [29] in the
meta-analysis published by Khanna et al [30]. Further-
more, relative weight was taken into account in the
Khanna report but not in the Stocken report. Thus each
of the meta-analyses has flaws in their design. The recent
meta-analysis by Khanna et al [30] investigated the effect
of adjuvant chemoradiotherapy compared with surgery
only. Five prospective studies with a total of 607 patients
(229 resected vs. 378 resected plus chemoradiotherapy)
were included. The 2-year OS rates reached 15-37% after
resection alone and 37-43% after resection and adjuvant
chemoradiotherapy. The percentage gain in survival from
adjuvant chemoradiotherapy was 3% - 27% despite the
absence of a statistically significant prolongation of sur-
vival in any of the individual studies. In total, an absolute
gain in survival of 12% was calculated after 2 years (95%
CI, 3%-21%, p = 0.011). However, the relative prolonga-
tion of survival decreased with more modern studies over
time and did not reach statistical significance in the latest
trials. A second meta-analysis from Stocken et al [28]
analysed adjuvant chemoradiotherapy and adjuvant che-
motherapy. Adjuvant chemotherapy improved survival in
patients with R0 resections but this benefit was not seen
with adjuvant chemoradiotherapy. The group concluded
that adjuvant/additive chemoradiotherapy is only more
effective than chemotherapy after R1-resections. For this
patient group the meta-analysis showed a reduction of
the hazard ratio by 28% (s.d. 19), whereas adjuvant che-
motherapy showed no significant effect on survival. A
retrospective study in additive chemoradiotherapy by
Wilkowski et al after R1-resections also reported excel-
lent survival data [31].
In summary, the value of adjuvant therapy is currently a
matter of great controversy. To date, seven randomised
phase III studies on the use of adjuvant CRT and adjuvant
chemotherapy have been conducted, the most important
of which are summarised in Table 1[17-19,22,23]. The
fully published studies which comprise CRT [17,18,22,23]
have substantial shortcomings as to the design and the
realisation of radiotherapy as discussed in detail else-
where [32]. Therefore, the efficacy of adjuvant CRTBrunner and Scott-Brown Radiation Oncology 2010, 5:64
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according to current quality standards is uncertain. This
unsatisfactory situation on the significance of adjuvant
CRT can be summarized in the following way:
• The European and the American trials are based 
upon different treatment paradigms. Whilst in North 
America CRT is regarded as one of the options of 
standard of care based on the GITSG- and RTOG-
data [18], in Europe adjuvant chemotherapy is prefer-
entially given.
• To define the role of adjuvant CRT, a large ran-
domised study exploiting the full options of the 
respective therapeutic modules needs to be planned 
carefully and interdisciplinary. Such a study should be 
accompanied by intensive therapeutic monitoring 
and be stratified by tumour location, resection status, 
nodal status and tumour size as identified in the 
RTOG 97-04 trial.
Summary
After R0-resection, patients should receive adjuvant che-
motherapy in the light of the relatively weak data to sup-
port the use of adjuvant CRT. Therefore patients should
not be treated with CRT outside of clinical trials in the
adjuvant situation. Those patients most likely to benefit
from adjuvant CRT would be expected to be patients with
tumours of the pancreatic head, pN1-status and a maxi-
mal tumour diameter of >3 cm. Additive CRT should be
considered after R1-resection.
Neoadjuvant therapy
The concept that neoadjuvant CRT may be more effective
than adjuvant CRT has been supported recently in resec-
table rectal carcinoma with a high risk for local relapse
(German Rectal Cancer Group). Neoadjuvant chemora-
diotherapy resulted in tumour regression causing a
higher rate of R0-resections, improved local control and
lower long term to xicity com pared with post -operative
chemoradiotherapy [33]. In pancreatic carcinoma the sit-
uation may be similar: general radiobiological consider-
ations suggest increased efficacy of preoperative
treatment due to a more effective chemotherapy delivery
with an intact blood supply, compared to the reduction of
blood flow and increased hypoxia in the post-operative
situation. Hypoxia is one of the most important factors of
radiation resistance [34]. Another problem in post-opera-
tive treatment is that the gastrointestinal reconstruction
receives the full dose of radiotherapy and postoperatively
dose is therefore limited to avoid injury to the anastomo-
sis of the reconstructed bowel. Beyond these radiobiolog-
ical considerations there are clinical implications
Table 1: Phase III-studies for adjuvant therapy
Group - Study 
Year
Patients (n) Inclusion 
criteria 
Resection-
Status
Treatment 
arms
Median 
overall 
survival 
(Months)
p-value Preoperative 
imaging
GITSG-
1985[18]
49 R0 CRT
Observation
21.0
10.9
0.005 No
EORTC-
1999[22]
114* R0 CRT
Observation
17.1
12.6
0.099 No
ESPAC-1-
2004[17]
289# R0 or R1 Cx
No Cx&
21.6
16.9
Not available No
CONKO-001-
2007[19]
368 R0 or R1 Cx
Observation
22.1
20.2
0.06 Yes
RTOG 9704 
2008[20]
442^ R0 or R1 CRT + GEM
CRT + 5-FU
20.6
16.9
0.033 Yes
Abbreviations: 5-FU = 5-fluorouracil, CRT= chemoradiotherapy, Cx= chemotherapy, GEM= gemcitabine, n= number, R0 = clear resection, R1 
= microscopically positive margins. Median overall survival rates from five randomized studies in patients with resected pancreatic 
carcinoma. None of these studies employed postoperative imaging to exclude tumour persistence or distant metastasis. *The EORTC study 
included 218 patients with periampullary and pancreatic carcinoma. The figures in the table are based upon the 114 patients with pancreatic 
carcinoma. #The ESPAC-1 study included 541 patients, but only 289 were included into the 2 × 2 factorial randomization. Arms: observation, 
chemotherapy, chemoradiotherapy, chemoradiotherapy followed by chemotherapy. The survival rates are given for the best treatment arm 
(chemotherapy) and observation. &The comparison arm comprises both, patients with observation and patients with chemoradiotherapy. 
^The RTOG 9704-study included a total of 442 patients, 380 of them had pancreatic head tumours.Brunner and Scott-Brown Radiation Oncology 2010, 5:64
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supporting the hypothesis that neoadjuvant chemoradio-
therapy could be more effective than adjuvant treat-
ment[35]: (1) Timely access to adjuvant therapy is
problematic after pancreaticoduodenectomies because
delayed post-operative recovery often does not allow
patients to start within 6 to 8 weeks of surgery [20]. (2)
Neoadjuvant therapy may allow better selection of
patients appropriate for surgical resection. Patients with
aggressive tumour biology and early evidence of meta-
static disease during the time of neoadjuvant treatment
can be spared a surgical procedure. This can be illus-
trated with the overall survival curves of two adjuvant
phase 3 studies: the CONKO-001 and the ESPAC-1 trial,
both show a complete overlap of the survival curves dur-
ing the first 12 months after surgery pointing to ineffec-
tive therapy for patients with an aggressive tumour
biology[17,19]. The same observation can be made in a
preoperative ECOG phase II trial including 53 patients
which reported six patients (11%) with distant metastasis
precluding surgery after preoperative chemoradiotherapy
[36]. (3) Neoadjuvant therapy may improve R0 resection
rates due to killing of cancer cells beyond the macroscop-
ically visible tumour and so decrease local failure rates as
suggested by intra-institutional comparisons between
pretreated and non-pretreated patients at the MD Ander-
son Cancer Center and the Fox Chase Cancer Center
[11,37]. Neoadjuvant therapy may also reduce the num-
ber of positive nodes [38].
The efficacy of neoadjuvant treatment can only be
deduced from phase II-studies or retrospective reports
because no prospectively randomised phase III-study has
been published at present. In a prospective comparative
study at the Mount Sinai Hospital in New York City [39]
laparotomy and/or CT followed by EUS, angiography or
laparoscopy was used to determine potential resectability
prior to therapeutic intervention. Patients with locally
invasive tumours deemed to be non-resectable as defined
in the report (T3, N0-1, M0; TNM 1997; n = 68) were
treated with split-course-chemoradiotherapy (5-FU,
streptozotocin and cisplatin) and subsequently surgery if
rendered amenable to resection. It should be noted that
conventionally non-resectable tumours are defined as
stage III (T4 N0-1 M0). Resectable tumours (T1-2, N0-1,
M0; n = 91) underwent immediate pancreaticoduodenec-
tomy. Sixty-three of 91 patients received adjuvant radio-
therapy or chemotherapy. Thirty of 68 patients with
initially irresectable tumours underwent surgery with
downstaging observed in 20 patients. The first CT re-
staging was performed after 10 weeks. Delayed response
on CT scans after chemoradiotherapy has often been
reported and repeated reassessment of resectability could
have increased resectability rates in this trial. The median
OS time of all patients receiving preoperative treatment
was 23.6 months compared to 14.0 months for patients
who had initial tumour resection (p = 0.006). This is an
unexpected result and possible explanations could be that
chemotherapy was continued routinely after chemora-
diotherapy resulting in a median OS of 18 months in the
patients without surgery. The chemoradiotherapy regi-
men was unusual with 54 Gy and two splits as well as
combined 5-fluorouracil, streptozotocin, and cisplatin
and it is not clear how much this has contributed to the
effectiveness in the experimental arm. On the other hand
the 14 month median OS for the primary resected
patients is considerably lower compared to the observa-
tional arm of the recently published CONKO-001 trial.
Part of this may be explained by surgical technique.
A group of 86 patients were treated with neoadjuvant
chemoradiotherapy (30 Gy in 10 fractions) with concur-
rent gemcitabine (400 mg/m²/week) at the M.D. Ander-
son Cancer Center [11]. Surgery was performed eleven to
twelve weeks later . This resulted in 74% of the patients
undergoing tumour resection. Better efficacy was
observed after gemcitabine concurrent with radiotherapy
[11] compared to previous studies from the same group
combining radiotherapy with 5-FU [40,41] Pathological
tumour response grading was ≥50% in 58% of the
resected tumours. Median OS time of the patients was 36
months. At the Duke University Medical Center in Dur-
ham, North Carolina, 111 patients with non-metastatic
pancreatic carcinoma were treated with chemoradiother-
apy (45 Gy, 5.4 Gy Boost, 5-FU/MMC/cDDP) [42]. Sev-
enty-two percent had a R0-resection and 70% were staged
ypN0 (y = posttreatment). The total survival rate of the
resected patients was 32% after 2 years. In our own expe-
rience 58 patients were resected without any neoadjuvant
therapy and had a median OS of 21 months whereas 21
patients with initially unresectable tumours underwent
CRT followed by resection and had a median OS of 54
months [43]. The small number of patients in the group
with neoadjuvant chemoradiotherapy is of course a limit-
ing factor in this comparison as reflected in the p value (p
= 0.084). A summary of the relevant studies to date is
shown in Table 2. Very recently, a systematic review and
meta-analysis on neoadjuvant therapy in 4,394 patients
(CRT in 94% and chemotherapy in 6%) showed that those
patients categorised to be non-resectable before treat-
ment but having resection after neoadjuvant treatment
had comparable survival (median overall survival 20.5
months) to patients with initially resectable tumours
(median overall survival 23.3 months) [44].
The first multicenter randomised study for neoadjuvant
therapy in pancreatic carcinoma is currently recruiting
[45]. This study will compare the outcomes of patients
treated with neoadjuvant CRT plus resection with those
treated with immediate resection in individuals whose
disease is considered to be resectable at diagnosis. The
resection is followed by adjuvant chemotherapy in bothBrunner and Scott-Brown Radiation Oncology 2010, 5:64
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Table 2: Selected studies of neoadjuvant chemoradiotherapy
Study 
Institution
Number of 
patients
Total dose of 
RT (Gy)
Chemo-
therapy
Median OS 
(months)
1(2,4,5)-
year-OS-rate 
(%)
Rate of local 
recurrence 
(%)
Rate of 
resectability 
(%)
Rate of clear 
resections
Hoffman et 
al. 
1998[36,74]
multi-
centric*
53 50.4 5-FU/MMC 9.7 all pts 
15.7 res
2y: 27 res 24/53 (26%) 
3/24 (13%) 
res
24/53 (45%) n.a.
Snady et al. 
2000[39]
Mount Sinai*
159
68* (20 res*)
vs 91 adj
54 +14 Gy 5-FU/Cis/
Streptozotocin
23.6* (32 res)
vs 14.0
1 y:
86*(89)vs 64
2y:
58*(60) vs 32
3y:
27*(40)vs 17
n.a. 20/68 (29%) - 95% neo 84% 
adj
Breslin et al. 
2001[75]
MDACC#
132 45 or 50.4 Gy
or 10 × 3 Gy
± IORT
5-FU, or Tax or 
Gem
21 1y: 75
2y: 40
5y: 23
8/132 (6%) - 88%
Sasson AR et 
al.2003[76]
FCCC*
116
61 neo
55 adj
50.4 5-FU/MMC or 
Gem
All 18 neo 23 
adj 16
n.a. n.a. - 39%
n.a.
n.a.
White et al. 
2005[68]
Duke#
193
i.p.r.:102
i.l.a.: 91
45 +5.4 Gy 5-FU
or Gem
23
39 i.p.r.
20 i.l.f.
3y: 37 res
5y: 27 res
n.a. 70/193 (36%)
54/102 (53%)
16/91 (18%)
73%
n.a.
n.a.
Evans et al. pII 
2008[11] * 
MDACC
i.p.r.: 86
(64 res)
30 Gy
(in 10 
fractions)
Gem
(7 × 400 mg)
23
34
1y: 92 res
2y: 62 res
5y: 36 res
7/64 (11%) 64/86 (74%) 11%
Golcher et al. 
2008[43]# 
Erlangen
79
21 neo*
58 res^
50.4 Gy
+5.4 Gy
5-FU
or Gem
54 neo-res
21 no CRT res
2y: 56 neo-res
43 no CRT res
n.a. 21/103(20%) 90% neo
78% res
Gillen et al. 
meta-
analysis 
2010[44]
All: 4,394
i.p.r.: 32%
i.l.a.: 51%
both: 17%
>60%: 40-60 
Gy
50% 5-FU(+)
40% Gem(+)
i.p.r.: 23
i.l.a.: 21
i.p.r/i.l.a.
1y 78/78
2y 47/50
n.a. i.p.r.: 74%
I.l.a.: 33%
i.p.r.: 82%
I.l.a.: 79%
Stessin et al. 
SEER 
2008[35]
i.p.r.: 3,885
70 neo
1,478 adj RT
2,337 obs
n.a. n.a. 23 neo
17 adj
12 obs
Neo/adj/obs
1y 79/68/50
2y 49/34/28
n.a. n.a. n.a.
Abbreviations: (+) = or additional agent, 5-FU = 5-fluorouracil; adj = adjuvant therapy; Cis = cisplatin; FCCC = Fox Chase Cancer Center, 
Philadelphia, PA; Gem = gemcitabine; Gy = Dose in Gray; i.p.r = initially potentially resectable; i.l.a. = initially locally advanced, MDACC = M.D. 
Anderson Cancer Center Houston, TX; MMC = mitomycin C; n.a. = not available; neo = neoadjuvant; obs. = observation, no adjuvant therapy, OS 
= overall survival; res = resected patients, RT = radiotherapy; Tax = paclitaxel; vs. = versus.
*initially unresectable patients ± resection after chemoradiotherapy;
§this study indicates overall survival as explained: (1) patients with chemoradiotherapy (2) numbers in brackets: patients with 
chemoradiotherapy and resection (3) numbers to the right of 'vs.': patients after primary resection.
^This study compared patients with immediate tumour resection (n = 58) with non-resectable patients who subsequently underwent 
neoadjuvant chemoradiotherapyBrunner and Scott-Brown Radiation Oncology 2010, 5:64
http://www.ro-journal.com/content/5/1/64
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arms. Because of the unique position of this study in the
neoadjuvant setting this study is highly relevant and
interested potential study centres are welcome to partici-
pate.
Summary
No conclusions can be drawn to date regarding the use of
neoadjuvant therapy. Neoadjuvant therapy is expected to
prolong survival by achieving higher rates of curative
resections (R0), ypN0-tumours and increased local
tumour control. Patients with resectable tumours at diag-
nosis should not be treated with neoadjuvant CRT out-
side of clinical trials. In patients with locally advanced,
initially unresectable tumours, chemoradiotherapy allows
secondary resectability in about 10-20% of the patients.
Locally advanced tumours
About one third of the patients with PDAC present with
locally advanced pancreatic cancer (LAPC) at diagnosis.
T h e  d e f i n i t i o n  o f  LA PC  i s  u n r e s e c t a b l e  d i s e a s e  i n  t h e
absence of distant metastases. Recently, the NCCN Prac-
tice Guidelines in Oncology have been published and
these distinguish between resectable, borderline resect-
able and unresectable disease [46]. Borderline resectable
tumours should be regarded as LAPC because of the high
likelihood of achieving an incomplete (R1 or R2) resec-
tion. Patients with LAPC are potentially curable if a clear
resection (R0) can be performed after downstaging of the
tumour and therefore should be treated with the inten-
tion of cure. Nevertheless, there is an ongoing contro-
versy about optimal therapy for this group of patients.
Chemoradiotherapy v Best Supportive Care
The advantage of chemoradiotherapy over best support-
ive care was tested in a small prospectively randomised
trial (16 vs 15 patients)[47]. Overall survival was signifi-
cantly longer, the quality of life significantly better and
the rate of distant metastases significantly lower in the
chemoradiotherapy group.
Chemoradiotherapy v Radiotherapy
Early randomised studies showed that combined CRT
(with total radiotherapy doses of 40 Gy and 5-FU) fol-
lowed by additive chemotherapy was superior to radio-
therapy alone [48,49]. In the GITSG trial [49] patients
were randomised to either radiotherapy or CRT (40 Gy)
or high dose CRT (60 Gy). Combined CRT was signifi-
c a n t l y  s u p e r i o r  t o  r a d i o t h e r a p y  a l o n e ,  w i t h  m e a n  O S
times of 10.4 vs 6.3 months. The problem with the radio-
therapy techniques at that time was that large volumes of
the small intestine were irradiated which lead to dose-
limiting toxicity [17,50]. Even if the studies on LAPC are
not fully consistent [51], there is general consensus that
radiotherapy should be given concurrently with chemo-
therapy in LAPC.
Chemoradiotherapy v Chemotherapy
Previous randomised phase II studies comparing CRT
with chemotherapy showed some superiority of CRT in
terms of local control and OS (Table 3)[50,52]. Yet, a
recent report from a phase III-trial [53] resulted in infe-
rior results following CRT . It should be noted however
that the standards of radiotherapy delivery in this trial
were sub-optimal with unusually high levels of radiother-
apy induced side-effects. In addition the investigators
used an unusual chemotherapy regimen (5-FU and cispl-
atin) that would not be considered standard in this set-
ting. The results of a recently published meta-analysis
[54] cannot resolve the problem of an imbalanced com-
parison of chemotherapy with chemoradiotherapy
because this meta-analysis includes only the early trials
from the 1980's and the report of the FFCD trial as dis-
cussed above [53]. The only study (ECOG4201) using
modern radiotherapy techniques was reported in 2008 by
Loehrer and coworkers as an abstract [55]. Thirty-eight
patients treated with gemcitabine alone were compared
to 36 patients treated with gemcitabine-based chemora-
diotherapy. There was no difference in partial response
rate in the two treatment groups, but significantly more
patients achieved stable disease in the chemoradiother-
apy arm (68% vs 35%). At the same time fewer patients
had progressive disease in the chemoradiotherapy arm
(6% vs 16%). Overall survival was statistically longer after
chemoradiotherapy compared to chemotherapy (p =
0.034; 12 m-OS 50% vs 32%; 18 m-OS 29% vs 11%, 24 m-
OS 12% vs 4%; mOS 11.0 vs 9.2 m). The increased toxicity
of chemoradiotherapy in this study compared to chemo-
therapy is probably attributable to the unusually high
dosing of gemcitabine (600 mg/m*/week for six weeks) in
conjunction with radiotherapy. The predominant grade
3/4 toxicities were fatigue and gastrointestinal side
effects. This trial was closed after recruitment of 74
patients whilst the accrual target was 316 patients.
Many chemotherapy trials included both patients with
locally advanced and metastatic disease. However, only
those studies with a subgroup analysis for LAPC allow for
an indirect comparison with radiotherapy. Four ran-
domised phase III-studies are suitable for such a compar-
ison [56-59] and the achieved median OS times ranged
between 6 and 12 months with a 1-year survival rate of
15%. More recently 3 phase III-studies which randomised
between gemcitabine monotherapy and gemcitabine
based chemotherapy combinations and which stratified
for LAPC and metastatic disease [60-62] have been
reported. Median OS was between 8.7 and 11.7 months
in the LAPC subgroups. Recent phase II-studies and
cohort studies employing CRT reported median OS
times of 10-11 months and 1-year-survival rates of up to
40% [47,63-66]. The value and particularly the toxicity of
additive chemotherapy before or after CR T ha ve to beBrunner and Scott-Brown Radiation Oncology 2010, 5:64
http://www.ro-journal.com/content/5/1/64
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further assessed in studies. Combinations of CRT and
chemotherapy reported median OS times of 13 - 15
months [24,64,67]. Currently this approach is further
evaluated in the international phase III LAP07 trial ran-
domising patients with LAPC who do not progress after
four months of chemotherapy with gemcitabine between
a CRT with concurrent capecitabine versus two more
cycles of gemcitabine.
Resectability should be re-evaluated 6-8 weeks after
completion of CRT to exploit the possibility of a curative
resection [39,68-73] but it should also be noted that
tumour response may appear several months after CRT is
Table 3: Selected studies for locally advanced pancreatic cancer employing chemoradiation ± chemotherapy
Trial
(patients)
Chemotherapy* Radiotherapy (Gray) Median survival (months) p-value
Johnson[59]
(129)
Lithium Gamonelate - 5.4 n.a.
Maisey[56]
(44/46)
5/FU PVI
5-FU/MMC
- 32% 1 year
43% 1 year
n.a.
Louvet[60]
(47/50)
Gem
Gem/Ox
-
-$
10.3
10.3
p = n.s.
Rocha Lima[61]
(24/27)
Gem
Gem/Iri
-
-$
11.7
9.8
p = n.s.
Van Cutsem[62]
(80/82)
Gem
Gem/tipifarnib
-8 . 7
11
p = n.s.
GITSG 1985[77]
(25/83/86)
-
5-FU
5-FU
60
40
60
5.2
9.6
9.2
p < 0.01
GITSG 1988[50]
(24/24)
SMF
SMF
54
-
6.5
5.1
p < 0.02
Klaassen[52]
(44/47)
5-FU
5-FU
40
-
8.3
8.2
n.a.
Chauffert[53]
(59/60)
5-FU (PVI)/Cis+Gem
Gem
60
-
8.0
14.5
p = 0.03
Loehrer[55]
(36/38)
Gem + Gem
Gem
50.4
-
11.0
9.2
p = 0.034
Crane[66]
(53/61)
Gem
5-FU (PVI)
30 (10#) 11
9
p = n.s.
Li[78]
(18/16)
Gem
5-FU
50.4 14.5
6.7
p = 0.027
Ishii[63]
(20)
5-FU (PVI) 50.4 10.3 n.a.
McGinn[65]
(37)
Gem 24-42 11.6 n.a.
Shinchi[47]
(16/15)
5-FU(PVI)
Supportive care
50.4
-
13.2
6.4
n.a.
Brunner[67]
(40/42)
Gem/Cis + Gem
Gem/Cis
55.8
55.8
13 8 p < 0.0001
Huguet[24]
(72/56)
5-FU (PVI)+ as below
FolFuGem, GemOx
55
-
15
11.7
p = 0.0009
Kachnic[64]
(23)
5-FU + Gem 50.4 13 n.a.
*: bold and italics indicate chemotherapy given as concurrent chemoradiotherapy #: radiotherapy fraction number; $: a chemotherapy only 
trial, but very few patients had some radiotherapy; 5-FU: 5-fluorouracil bolus injection unless marked as 'PVI'; Cis: cisplatin; Gem: gemcitabine; 
Fol: folinic acid; Iri: irinotecan; MMC: mitomycin C; n.a.: not available; n.s.: not significant; Ox: oxaliplatine; PVI: protracted venous infusion, SMF: 
streptozotocin, mitomycin, 5-fluorouracil.Brunner and Scott-Brown Radiation Oncology 2010, 5:64
http://www.ro-journal.com/content/5/1/64
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completed. Curative resection (R0) can be performed in
10-20% of the patients who initially presented with
LAPC.
Summary
A direct comparison of CRT and chemotherapy is cur-
rently difficult. After the recent presentation of the data
from the ECOG 4201 trial this result is pointing to supe-
riority of CRT but requires further validation in clinical
trials to test if modern-technique chemoradiotherapy is
indeed superior to chemotherapy for LAPC because of
the small sample size due to poor accrual. However , as
expected toxicity is higher with chemoradiotherapy and
should be reduced by optimised techniques. Additive
chemotherapy before or after CRT needs to be tested in
randomised studies. The most important argument for
CRT is a 10-20% rate of secondary resectability. This has
not been reported with chemotherapy alone.
Clinical consequences
-After R0 resections, the current evidence supports 
the use of adjuvant chemotherapy rather than chemo-
radiotherapy followed by chemotherapy, even if 
chemoradiotherapy is regarded as the standard of 
care in North America.
-After R1-resections adjuvant chemotherapy followed 
by chemoradiotherapy should be considered.
-Evidence for the role of neoadjuvant chemoradio-
therapy is expected from currently open randomised 
trials and eligible patients should be offered entry into 
these trials.
-In order to overcome the poor prognosis associated 
with locally advanced disease it is important to con-
front the nihilistic beliefs of clinicians. It should be 
remembered that CRT confers a secondary resect-
ability rate of 10 - 20% offering these patients the 
prospect of curative treatment.
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